Toward Replacing Late Gadolinium Enhancement With Artificial Intelligence Virtual Native Enhancement for Gadolinium-Free Cardiovascular Magnetic Resonance Tissue Characterization in Hypertrophic Cardiomyopathy

Supplemental Digital Content is available in the text. Background: Late gadolinium enhancement (LGE) cardiovascular magnetic resonance (CMR) imaging is the gold standard for noninvasive myocardial tissue characterization but requires intravenous contrast agent administration. It is highly desired to develop a contrast agent–free technology to replace LGE for faster and cheaper CMR scans. Methods: A CMR virtual native enhancement (VNE) imaging technology was developed using artificial intelligence. The deep learning model for generating VNE uses multiple streams of convolutional neural networks to exploit and enhance the existing signals in native T1 maps (pixel-wise maps of tissue T1 relaxation times) and cine imaging of cardiac structure and function, presenting them as LGE-equivalent images. The VNE generator was trained using generative adversarial networks. This technology was first developed on CMR datasets from the multicenter Hypertrophic Cardiomyopathy Registry, using hypertrophic cardiomyopathy as an exemplar. The datasets were randomized into 2 independent groups for deep learning training and testing. The test data of VNE and LGE were scored and contoured by experienced human operators to assess image quality, visuospatial agreement, and myocardial lesion burden quantification. Image quality was compared using a nonparametric Wilcoxon test. Intra- and interobserver agreement was analyzed using intraclass correlation coefficients (ICC). Lesion quantification by VNE and LGE were compared using linear regression and ICC. Results: A total of 1348 hypertrophic cardiomyopathy patients provided 4093 triplets of matched T1 maps, cines, and LGE datasets. After randomization and data quality control, 2695 datasets were used for VNE method development and 345 were used for independent testing. VNE had significantly better image quality than LGE, as assessed by 4 operators (n=345 datasets; P<0.001 [Wilcoxon test]). VNE revealed lesions characteristic of hypertrophic cardiomyopathy in high visuospatial agreement with LGE. In 121 patients (n=326 datasets), VNE correlated with LGE in detecting and quantifying both hyperintensity myocardial lesions (r=0.77–0.79; ICC=0.77–0.87; P<0.001) and intermediate-intensity lesions (r=0.70–0.76; ICC=0.82–0.85; P<0.001). The native CMR images (cine plus T1 map) required for VNE can be acquired within 15 minutes and producing a VNE image takes less than 1 second. Conclusions: VNE is a new CMR technology that resembles conventional LGE but without the need for contrast administration. VNE achieved high agreement with LGE in the distribution and quantification of lesions, with significantly better image quality.

[1]  Stefan K. Piechnik,et al.  Deep neural network ensemble for on-the-fly quality control-driven segmentation of cardiac MRI T1 mapping , 2021, Medical Image Anal..

[2]  Stefan L. Zimmerman,et al.  Quality assurance of quantitative cardiac T1-mapping in multicenter clinical trials – A T1 phantom program from the hypertrophic cardiomyopathy registry (HCMR) study , 2021, International journal of cardiology.

[3]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[4]  Konrad Werys,et al.  Deep learning with attention supervision for automated motion artefact detection in quality control of cardiac T1-mapping , 2020, Artif. Intell. Medicine.

[5]  Iulia A. Popescu,et al.  Standardization of T1-mapping in cardiovascular magnetic resonance using clustered structuring for benchmarking normal ranges. , 2020, International journal of cardiology.

[6]  V. Ferreira,et al.  Cardiovascular Magnetic Resonance for the Differentiation of Left Ventricular Hypertrophy , 2020, Current Heart Failure Reports.

[7]  Víctor M. Campello,et al.  Cardiac Segmentation on Late Gadolinium Enhancement MRI: A Benchmark Study from Multi-Sequence Cardiac MR Segmentation Challenge , 2020, Medical Image Anal..

[8]  E. Nagel,et al.  Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update , 2020, Journal of Cardiovascular Magnetic Resonance.

[9]  J. Xu,et al.  MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction. , 2019, Radiology.

[10]  M. Dweck,et al.  Myocardial fibrosis: why image, how to image and clinical implications , 2019, Heart.

[11]  Víctor M. Campello,et al.  Combining Multi-Sequence and Synthetic Images for Improved Segmentation of Late Gadolinium Enhancement Cardiac MRI , 2019, STACOM@MICCAI.

[12]  D. Rueckert,et al.  Unsupervised Multi-modal Style Transfer for Cardiac MR Segmentation , 2019, STACOM@MICCAI.

[13]  S. Solomon,et al.  A First in Human Study of the Selective Cardiac Myosin Inhibitor, CK-3773274 , 2019, Journal of Cardiac Failure.

[14]  J. Seidman,et al.  Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. , 2019, Circulation research.

[15]  A. Owens,et al.  Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy , 2019, Annals of Internal Medicine.

[16]  R. Blankstein,et al.  Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis , 2019, Journal of Cardiovascular Magnetic Resonance.

[17]  J. Cornel,et al.  The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. , 2018, JACC. Cardiovascular imaging.

[18]  J. Pauly,et al.  Deep learning enables reduced gadolinium dose for contrast‐enhanced brain MRI , 2018, Journal of magnetic resonance imaging : JMRI.

[19]  Philip H. S. Torr,et al.  Learn To Pay Attention , 2018, ICLR.

[20]  Richard B. Thompson,et al.  Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI) , 2017, Journal of Cardiovascular Magnetic Resonance.

[21]  S. Piechnik,et al.  State-of-the-art review: stress T1 mapping—technical considerations, pitfalls and emerging clinical applications , 2017, Magnetic Resonance Materials in Physics, Biology and Medicine.

[22]  Einar Heiberg,et al.  Sources of variability in quantification of cardiovascular magnetic resonance infarct size - reproducibility among three core laboratories , 2017, Journal of Cardiovascular Magnetic Resonance.

[23]  K. Sugimura,et al.  Radiologic-Pathologic Correlation of Primary and Secondary Cardiomyopathies: MR Imaging and Histopathologic Findings in Hearts from Autopsy and Transplantation. , 2017, Radiographics : a review publication of the Radiological Society of North America, Inc.

[24]  K. Diao,et al.  Histologic validation of myocardial fibrosis measured by T1 mapping: a systematic review and meta-analysis , 2016, Journal of Cardiovascular Magnetic Resonance.

[25]  R. Chan,et al.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. , 2016, JACC. Cardiovascular imaging.

[26]  Alexei A. Efros,et al.  Image-to-Image Translation with Conditional Adversarial Networks , 2016, 2017 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).

[27]  Li Fei-Fei,et al.  Perceptual Losses for Real-Time Style Transfer and Super-Resolution , 2016, ECCV.

[28]  Martín Abadi,et al.  TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems , 2016, ArXiv.

[29]  Daniel Messroghli,et al.  State of the Art: Clinical Applications of Cardiac T1 Mapping. , 2016, Radiology.

[30]  N. Geller,et al.  Hypertrophic Cardiomyopathy Registry: The rationale and design of an international, observational study of hypertrophic cardiomyopathy. , 2015, American heart journal.

[31]  Thomas Brox,et al.  U-Net: Convolutional Networks for Biomedical Image Segmentation , 2015, MICCAI.

[32]  Jimmy Ba,et al.  Adam: A Method for Stochastic Optimization , 2014, ICLR.

[33]  Martin Borggrefe,et al.  [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy]. , 2014, Kardiologia polska.

[34]  Martin Rajchl,et al.  Accuracy and reproducibility of semi-automated late gadolinium enhancement quantification techniques in patients with hypertrophic cardiomyopathy , 2014, Journal of Cardiovascular Magnetic Resonance.

[35]  Andrew Zisserman,et al.  Very Deep Convolutional Networks for Large-Scale Image Recognition , 2014, ICLR.

[36]  Michael S. Bernstein,et al.  ImageNet Large Scale Visual Recognition Challenge , 2014, International Journal of Computer Vision.

[37]  Stefan Neubauer,et al.  T1 measurements in the human myocardium: The effects of magnetization transfer on the SASHA and MOLLI sequences , 2013, Magnetic resonance in medicine.

[38]  Saurabh Shah,et al.  T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: a preliminary study. , 2013, European journal of radiology.

[39]  J. Duerk,et al.  Magnetic Resonance Fingerprinting , 2013, Nature.

[40]  Andrew S Flett,et al.  Human non-contrast T1 values and correlation with histology in diffuse fibrosis , 2013, Heart.

[41]  E. Nagel,et al.  European cardiovascular magnetic resonance (EuroCMR) registry – multi national results from 57 centers in 15 countries , 2013, Journal of Cardiovascular Magnetic Resonance.

[42]  Stefan Neubauer,et al.  Myocardial Tissue Characterization Using Magnetic Resonance Noncontrast T1 Mapping in Hypertrophic and Dilated Cardiomyopathy , 2012, Circulation. Cardiovascular imaging.

[43]  David Vancraeynest,et al.  Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. , 2012, Journal of the American College of Cardiology.

[44]  Francesca N. Delling,et al.  Intermediate-Signal-Intensity Late Gadolinium Enhancement Predicts Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy , 2012, Circulation. Cardiovascular imaging.

[45]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[46]  R. Kim,et al.  Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. , 2005, European heart journal.

[47]  E. McVeigh,et al.  Phase‐sensitive inversion recovery for detecting myocardial infarction using gadolinium‐delayed hyperenhancement † , 2002, Magnetic resonance in medicine.

[48]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[49]  Carsten Rother,et al.  Can Virtual Contrast Enhancement in Brain MRI Replace Gadolinium?: A Feasibility Study. , 2019, Investigative radiology.

[50]  Yang Yan-zon Interpretation of guidelines on 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy , 2012 .